



MARK B HORTON, MD, MSPH
Director

State of California—Health and Human Services Agency
California Department of Public Health



EDMUND G. BROWN JR.
Governor

**OFFICE OF AIDS
AIDS Drug Assistance Program (ADAP)**

**Management Memorandum
Memorandum Number: 2011-07**

Date: December 16, 2011

TO: ADAP LOCAL HEALTH JURISDICTION COORDINATORS AND ADAP
ENROLLMENT WORKERS

SUBJECT: ADDITION OF EMITRICITABINE/RILPIVIRINE/TENOFOVIR DF FDC
200mg/25mg/300mg TABLETS TO THE ADAP FORMULARY

Effective December 16, 2011, emtricitabine/rilpivirine/tenofovir DF (Complera) fixed dose combination (FDC) 200mg/25mg/300mg of FTC/RPV/TDF tablets will be added to the ADAP formulary. The U.S. Food and Drug Administration has approved emtricitabine/rilpivirine/tenofovir DF FDC for the treatment of HIV-1 infection in adults who are treatment naïve.

Emitricitabine/rilpivirine/tenofovir contains a non-nucleoside reverse transcriptase inhibitor (rilpivirine) and two nucleoside reverse transcriptase inhibitors (emtricitabine and tenofovir DF). Emitricitabine/rilpivirine/tenofovir DF FDC is to be taken orally once a day with food.

ADAP now has 183 drugs on the formulary.

If you have any questions regarding the addition of this medication to the ADAP formulary, please contact me at (916) 449-5943

Celia Banda-Brown, Chief
AIDS Drug Assistance Program Section
Office of AIDS